Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Inclusion Criteria: * Patients ≥ 18 and ≤75 years with type 2 diabetes; * HbA1c ≥ 7.5 to ≤11.0%; * Receipt of premixed insulin and/or oral anti-diabetic agents ≥ 12 weeks before enrollment in the study, and insulin dose adjustments ≤ 10% within 4 weeks before enrollment (dose adjustment = (the maximum dose within a month - the minimum dose) / Final dose (dose of the day before the visit) × 100%); * BMI ≤ 32kg / m2. Exclusion Criteria: * Patients with any of the following conditions will be excluded: * Pregnant or lactating women * Severe hypoglycemia within one month; diabetic ketoacidosis or hyperosmotic diabetic status within 6 months prior to informed consent * Myocardial infarction, stroke or other severe cardiovascular events within 6 months prior to informed consent * Current treatment with systemic steroids or immunosuppressive agents, or have immunologic deficiency disease at time of informed consent * Severe mental instability, or alcohol abuse, or drug abuse * Skin lesions at the insulin injection site * Cancer within 5 years prior to informed consent * Pancreatitis of severe infectious diseases within 1 months prior to informed consent * Known hypersensitivity or allergy to the insulin * Renal impairment (CKD-EPI eGFR\<60ml/min) * Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined * Participation in another trial within 2 months prior to informed consent * Patients that investigators believe may fail to complete the study